227 related articles for article (PubMed ID: 21658003)
1. Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides.
Zhao W; McCallum SA; Xiao Z; Zhang F; Linhardt RJ
Biosci Rep; 2012 Feb; 32(1):71-81. PubMed ID: 21658003
[TBL] [Abstract][Full Text] [Related]
2. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library.
Ashikari-Hada S; Habuchi H; Kariya Y; Itoh N; Reddi AH; Kimata K
J Biol Chem; 2004 Mar; 279(13):12346-54. PubMed ID: 14707131
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity.
Teran M; Nugent MA
J Biol Chem; 2015 Jun; 290(26):16451-62. PubMed ID: 25979342
[TBL] [Abstract][Full Text] [Related]
4. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor.
Dougher AM; Wasserstrom H; Torley L; Shridaran L; Westdock P; Hileman RE; Fromm JR; Anderberg R; Lyman S; Linhardt RJ; Kaplan J; Terman BI
Growth Factors; 1997; 14(4):257-68. PubMed ID: 9386990
[TBL] [Abstract][Full Text] [Related]
5. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.
Robinson CJ; Mulloy B; Gallagher JT; Stringer SE
J Biol Chem; 2006 Jan; 281(3):1731-40. PubMed ID: 16258170
[TBL] [Abstract][Full Text] [Related]
6. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.
Gengrinovitch S; Greenberg SM; Cohen T; Gitay-Goren H; Rockwell P; Maione TE; Levi BZ; Neufeld G
J Biol Chem; 1995 Jun; 270(25):15059-65. PubMed ID: 7797488
[TBL] [Abstract][Full Text] [Related]
7. Modulation of binding to vascular endothelial growth factor and receptor by heparin derived oligosaccharide.
Liu JR; Wang HF; Yu DF; Chen XY; He SY
Carbohydr Polym; 2017 Oct; 174():558-564. PubMed ID: 28821104
[TBL] [Abstract][Full Text] [Related]
8. Heparinase 1 selectivity for the 3,6-di-O-sulfo-2-deoxy-2-sulfamido-alpha-D-glucopyranose (1,4) 2-O-sulfo-alpha-L-idopyranosyluronic acid (GlcNS3S6S-IdoA2S) linkages.
Xiao Z; Zhao W; Yang B; Zhang Z; Guan H; Linhardt RJ
Glycobiology; 2011 Jan; 21(1):13-22. PubMed ID: 20729345
[TBL] [Abstract][Full Text] [Related]
9. Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis.
Cole CL; Hansen SU; Baráth M; Rushton G; Gardiner JM; Avizienyte E; Jayson GC
PLoS One; 2010 Jul; 5(7):e11644. PubMed ID: 20657775
[TBL] [Abstract][Full Text] [Related]
10. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins.
Ashikari-Hada S; Habuchi H; Kariya Y; Kimata K
J Biol Chem; 2005 Sep; 280(36):31508-15. PubMed ID: 16027124
[TBL] [Abstract][Full Text] [Related]
11. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.
Héroult M; Bernard-Pierrot I; Delbé J; Hamma-Kourbali Y; Katsoris P; Barritault D; Papadimitriou E; Plouet J; Courty J
Oncogene; 2004 Mar; 23(9):1745-53. PubMed ID: 15001987
[TBL] [Abstract][Full Text] [Related]
12. Octasaccharide is the minimal length unit required for efficient binding of cyclophilin B to heparin and cell surface heparan sulphate.
Vanpouille C; Denys A; Carpentier M; Pakula R; Mazurier J; Allain F
Biochem J; 2004 Sep; 382(Pt 2):733-40. PubMed ID: 15109301
[TBL] [Abstract][Full Text] [Related]
13. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites.
Goger B; Halden Y; Rek A; Mösl R; Pye D; Gallagher J; Kungl AJ
Biochemistry; 2002 Feb; 41(5):1640-6. PubMed ID: 11814358
[TBL] [Abstract][Full Text] [Related]
14. Influence of saccharide modifications on heparin lyase III substrate specificities.
Wu J; Chopra P; Boons GJ; Zaia J
Glycobiology; 2022 Mar; 32(3):208-217. PubMed ID: 33822051
[TBL] [Abstract][Full Text] [Related]
15. Uncovering the detailed mode of cleavage of heparinase I toward structurally defined heparin oligosaccharides.
Zhang C; Tang F; Zhang J; Cao J; Li H; Liu C
Int J Biol Macromol; 2019 Dec; 141():756-764. PubMed ID: 31479666
[TBL] [Abstract][Full Text] [Related]
16. Kinetic and structural studies on interactions between heparin or heparan sulfate and proteins of the hedgehog signaling pathway.
Zhang F; McLellan JS; Ayala AM; Leahy DJ; Linhardt RJ
Biochemistry; 2007 Apr; 46(13):3933-41. PubMed ID: 17348690
[TBL] [Abstract][Full Text] [Related]
17. The anti-angiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner.
Vanwildemeersch M; Olsson AK; Gottfridsson E; Claesson-Welsh L; Lindahl U; Spillmann D
J Biol Chem; 2006 Apr; 281(15):10298-304. PubMed ID: 16436387
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains.
Zhang W; Swanson R; Xiong Y; Richard B; Olson ST
J Biol Chem; 2006 Dec; 281(49):37302-10. PubMed ID: 17040907
[TBL] [Abstract][Full Text] [Related]
19. Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1.
Yu H; Tyrrell D; Cashel J; Guo NH; Vogel T; Sipes JM; Lam L; Fillit HM; Hartman J; Mendelovitz S; Panel A; Roberts DD
Arch Biochem Biophys; 2000 Feb; 374(1):13-23. PubMed ID: 10640391
[TBL] [Abstract][Full Text] [Related]
20. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors.
Soker S; Goldstaub D; Svahn CM; Vlodavsky I; Levi BZ; Neufeld G
Biochem Biophys Res Commun; 1994 Sep; 203(2):1339-47. PubMed ID: 7522446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
